The Board intends to seek acquisition opportunities in the life sciences and biotechnology sector. The Board’s current intention is that on completion of an acquisition in this new sector, the Board will seek admission of the Company’s issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange plc and to simultaneously cancel trading of its issues share capital on AIM. The Board is actively involved in the appraisal of opportunities